Synaptic Dysfunction Comparison in Neurodegenerative Diseases

📖 Wiki Page

mechanism2775 wordssynced 2026-04-02

title: Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Overview

Synaptic dysfunction is now recognized as one of the earliest and most critical pathological events in neurodegenerative diseases, preceding neuronal loss and often correlating better with cognitive decline than traditional neuropathological markers. While each disease has distinct primary pathological triggers, converging mechanisms lead to synaptic impairment across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and various tauopathies including corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP).

This comparison page examines the shared and disease-specific mechanisms of synaptic dysfunction, highlighting how different proteinopathies converge on synaptic failure and identifying therapeutic targets that may be relevant across multiple disorders.

Common Mechanisms of Synaptic Dysfunction

Despite the diverse primary pathologies in each neurodegenerative disease, several convergent mechanisms lead to synaptic impairment:

```mermaid
flowchart TD
subgraph Inputs["Primary Pathologies"]
A["Amyloid-beta oligomers"] --> D["Synaptic Dysfunction"]
B["Alpha-synuclein"] --> D
C["Tau pathology"] --> D
E["TDP-43 aggregation"] --> D
F["Mitochondrial dysfunction"] --> D
end

...

title: Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Overview

Common Mechanisms of Synaptic Dysfunction

Despite the diverse primary pathologies in each neurodegenerative disease, several convergent mechanisms lead to synaptic impairment:

Mermaid diagram (expand to render)

Calcium Dysregulation

Calcium homeostasis is essential for synaptic function, and dysregulation represents a common final pathway in neurodegenerative diseases. Multiple disease-specific mechanisms converge on calcium dysregulation:

AD: Amyloid-beta channels direct calcium influx into neurons; NMDA receptor overactivation leads to excitotoxicity
PD: Alpha-synuclein oligomers form calcium-permeable pores; mitochondrial dysfunction impairs calcium buffering
ALS: Mutant SOD1 affects calcium homeostasis in motor neurons; TDP-43 loss-of-function disrupts calcium-regulating genes
Tauopathies: Tau accumulation disrupts calcium signaling pathways; NMDA receptor alterations affect calcium influx

Oxidative Stress

Reactive oxygen species (ROS) accumulate in neurodegenerative brains and directly damage synaptic components:

Synaptic mitochondria are particularly vulnerable due to high energy demands
Lipid peroxidation damages synaptic membranes and vesicle function
Protein oxidation impairs synaptic scaffolding proteins and receptors
DNA oxidation in synaptic nuclei affects local gene expression

Neuroinflammation

Activated microglia and astrocytes release pro-inflammatory cytokines that modulate synaptic function:

TNF-α reduces synaptic currents and promotes spine elimination
IL-1β impairs LTP and synaptic plasticity
IL-6 affects neurotransmitter release and synaptic protein expression
Complement proteins tag synapses for elimination via microglia

Disease-Specific Synaptic Pathology

Alzheimer's Disease

Synaptic dysfunction in AD is driven primarily by amyloid-beta (Aβ) oligomers and tau pathology, with the relative contribution varying across disease stages.

Aβ-Mediated Synaptic Toxicity:

Aβ oligomers bind to synaptic receptors including NMDA receptors, AMPA receptors, and cellular prion protein (PrP^C)
Synaptic activity enhances Aβ production, creating a vicious cycle
Aβ disrupts glutamatergic synaptic transmission and plasticity
Soluble Aβ oligomers correlate better with cognitive decline than plaque burden

Tau-Mediated Synaptic Dysfunction:

Pathological tau accumulates in pre-synaptic terminals, affecting vesicle trafficking
Tau dissociates from microtubules, disrupting axonal transport of synaptic proteins
Post-synaptic tau affects NMDA receptor trafficking and dendritic spine morphology
Tau oligomers at synapses are particularly toxic

Synaptic Markers in AD:

| Marker | Change | Region | Stage |
|--------|--------|--------|-------|
| Synaptophysin | -25-65% | Hippocampus | Early |
| PSD-95 | -30-50% | Cortex | Early |
| Synapsin I | -20-40% | Hippocampus | Variable |
| NR2A/B | -35% | Cortex | Moderate |
| GluA1 | -40% | Hippocampus | Moderate |

See also: [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis), [Tau Pathology Pathway](/mechanisms/tau-pathology-pathway)

Parkinson's Disease

In PD, synaptic dysfunction occurs both from alpha-synuclein pathology and from dopaminergic neuron loss.

Alpha-Synuclein at the Synapse:

Alpha-synuclein is a pre-synaptic protein involved in vesicle trafficking
Pathological aggregation disrupts synaptic vesicle cycling
Lewy bodies form in synaptic terminals
Synaptic alpha-synuclein correlates with motor symptoms

Dopaminergic Synaptic Changes:

Loss of substantia nigra dopaminergic neurons disrupts striatal synapses
Dysregulated dopamine release affects corticostriatal plasticity
Non-dopaminergic circuits are also affected early

Synaptic Markers in PD:

| Marker | Change | Region | Reference |
|--------|--------|--------|-----------|
| Synaptophysin | -30-50% | Substantia nigra | [@synaptic2017] |
| VGLUT1 | -25-40% | Striatum | [@vglut2019] |
| TH | -50-70% | Substantia nigra | [@tyrosine2019] |

See also: [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway), [Dopaminergic Neuron Loss in Parkinson's](mechanisms/parkinsons-disease-mechanisms)

Amyotrophic Lateral Syndrome (ALS)

ALS features synaptic dysfunction at neuromuscular junctions and within central nervous system circuits.

Synaptic Pathology in ALS:

Neuromuscular junction denervation is an early event
Cortical hyperexcitability precedes motor neuron loss
TDP-43 aggregation affects synaptic RNA metabolism
Glutamate excitotoxicity contributes to synaptic failure

Key Mechanisms:

Excitotoxicity: Elevated glutamate, impaired transporters
mitochondrial dysfunction: Energy failure at synapses
Cytoskeletal defects: Impaired axonal transport
Non-cell autonomous: Glial contributions to synaptic loss

See also: [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

Frontotemporal Dementia (FTD)

FTD encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes, with synaptic loss being a key correlate of clinical decline.

Synaptic Pathology in FTD:

TDP-43 pathology (in most cases) disrupts synaptic RNA metabolism
Tau pathology (in rare cases) directly impairs synaptic function
Early loss of synaptic markers correlates with behavioral changes
Synaptic dysfunction precedes detectable atrophy

Key Mechanisms:

TDP-43 loss-of-function: Impaired synaptic protein synthesis
Neuronal hyperexcitability: Cortical disinhibition
Synaptic pruning: Enhanced complement-mediated elimination
Network dysfunction: Disrupted functional connectivity

Synaptic Markers in FTD:

| Marker | Change | Region | Reference |
|--------|--------|--------|-----------|
| Synaptophysin | -20-40% | Frontal cortex | [@synaptic2018] |
| PSD-95 | -25-45% | Temporal cortex | [@psd2018] |
| VAMP2 | -15-30% | Frontostriatal | [@vamp2019] |

See also: [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

Huntington's Disease (HD)

Huntington's disease features prominent corticostriatal synaptic vulnerability, representing a "dying-back" pattern of neurodegeneration.

Corticostriatal Synaptic Vulnerability:

Mutant huntingtin (mHTT) disrupts synaptic vesicle trafficking
Early loss of dendritic spines on medium spiny neurons (MSNs)
Excitotoxicity due to NMDA receptor dysregulation
Impaired axonal transport of synaptic proteins

Key Mechanisms:

Loss of wtHTT function: Essential for synaptic vesicle trafficking and spine maintenance
Toxic gain-of-function: mHTT aggregates sequester synaptic proteins
Excitotoxicity: NMDAR hyperactivity leads to calcium dysregulation
Transcriptional dysregulation: Reduced synaptic protein expression

Synaptic Markers in HD:

| Marker | Change | Region | Reference |
|--------|--------|--------|-----------|
| Synaptophysin | -30-50% | Striatum | [@synaptic2011] |
| PSD-95 | -25-40% | Cortex | [@cortical2015] |
| VGLUT1 | -20-35% | Corticostriatal | [@vglut2013] |

See also: [Huntington's Disease](/diseases/huntington-disease), [Corticostriatal Synaptic Vulnerability in HD](/mechanisms/huntingtons-corticostriatal-synaptic-vulnerability)

Tauopathies: CBS and PSP

Corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) provide unique insights into tau-specific synaptic toxicity.

4R Tau-Mediated Synaptic Dysfunction:

Pathological 4R tau accumulates in both pre- and post-synaptic compartments
Direct tau interactions with synaptic proteins impair function
Tau oligomers at synapses represent the toxic species

CBS-Specific Features:

Severe cortical synaptic loss, particularly in motor regions
Both pre-synaptic (vesicle cycle) and post-synaptic (receptor) impairment
Strong correlation between synaptic loss and cognitive decline

PSP-Specific Features:

Earlier brainstem synaptic involvement
Distinct clinical correlates (vertical gaze palsy)
Post-synaptic predominance in certain regions

See also: [CBS Synaptic Dysfunction](/mechanisms/cbs-synaptic-dysfunction), [Complement in Tauopathies](/mechanisms/complement-tauopathies-cbs)

Comparative Analysis

Cross-Disease Comparison Matrix

| Feature | AD | PD | ALS | FTD | HD | CBS | PSP |
|---------|-----|-----|-----|-----|-----|-----|-----|
| Primary driver | Aβ + Tau | α-syn | TDP-43 | TDP-43/GRN | mHTT | 4R Tau | 4R Tau |
| Synapse compartment | Pre + Post | Pre | Pre + Post | Pre + Post | Pre + Post | Pre + Post | Post dominant |
| Key marker change | Syn↓ 25-65% | Syn↓ 30-50% | Syn↓ 20-40% | Syn↓ 30-50% | Syn↓ 25-45% | Syn↓ 30-50% | Syn↓ 20-40% |
| LTP impairment | Severe | Moderate | N/A | Moderate | Moderate | Moderate | Moderate |
| Spine loss | Severe | Moderate | N/A | Moderate-severe | Moderate-severe | Moderate-severe | Moderate |
| Prion-like spread | Yes | Yes | Limited | Yes | Limited | Yes | Yes |

Temporal Pattern Comparison

Mermaid diagram (expand to render)

Therapeutic Approaches Targeting Synaptic Function

Direct Synaptic Protection

| Approach | Mechanism | Stage | Disease |
|----------|-----------|-------|---------|
| NMDA modulators | Reduce excitotoxicity | Approved (memantine) | AD |
| AChE inhibitors | Enhance cholinergic signaling | Approved | AD |
| AMPA modulators | Enhance glutamatergic transmission | Phase 2 | AD |
| Synaptic vesicle cycle enhancers | Improve vesicle function | Preclinical | PD |

Disease-Modifying Approaches

Anti-amyloid therapies may protect synapses by reducing Aβ-mediated toxicity:

Lecanemab (lecanemab) showed synaptic marker improvements in trials
Donanemab targets amyloid plaques

Anti-tau therapies may preserve synaptic function:

Tau aggregation inhibitors
Anti-tau antibodies
Tau phosphorylation modulators

Alpha-synuclein-targeting approaches:

Immunotherapies targeting α-syn
Small molecule aggregation inhibitors

Emerging Strategies

Synaptic regeneration: Exercise, environmental enrichment, stem cells
Neurotrophic factors: BDNF mimetics, gene therapy
Calcium homeostasis: Channel modulators, buffers

Clinical Trials Targeting Synaptic Function

Active and Recent Trials

| NCT ID | Title | Phase | Status | Intervention |
|--------|-------|-------|--------|--------------|
| NCT05531656 | START: Synaptic Therapy Alzheimer's Research Trial | Phase 2 | Active | Novel synaptic modulator |
| NCT05911178 | Impact of Microglial Activation on Synaptic Density | Observational | Recruiting | N/A |
| NCT07115238 | Phase 3 Study for Alzheimer's | Phase 3 | Recruiting | PET visualization |
| NCT07314190 | Synapsing Retrospective Biomarker Study | Observational | Enrolling | N/A |

Completed Trials

| NCT ID | Title | Phase | Status | Key Findings |
|--------|-------|-------|--------|--------------|
| NCT00040443 | CX516 in Mild Cognitive Impairment | Phase 2 | Completed | AMPAkine; modest cognitive effects |
| NCT00134953 | Rivastigmine in MCI | Phase 3 | Terminated | Did not meet primary endpoint |
| NCT00001662 | CX516 in Alzheimer's Disease | Phase 2 | Completed | Safety established |
| NCT02580305 | Novel synaptic therapy | Phase 2a | Completed | Dose-ranging completed |
| NCT00842816 | Davunetide trial | Phase 2 | Completed | Peptide; no significant benefit |
| NCT00219232 | Rivastigmine extension | Phase 3 | Completed | Long-term safety established |
| NCT00097916 | Galantamine efficacy | Phase 3 | Completed | Cognitive benefits maintained |
| NCT00948766 | Donepezil study | Phase 4 | Completed | Clinical efficacy confirmed |

Cholinergic Trials

| NCT ID | Title | Phase | Status |
|--------|-------|-------|--------|
| NCT00403520 | Donepezil vs Placebo | Phase 4 | Completed |
| NCT00253227 | Galantamine Flexible Dose | Phase 3 | Completed |
| NCT00099242 | Rivastigmine Patch | Phase 3 | Completed |
| NCT00348309 | 54-week Rivastigmine | Observational | Completed |
| NCT02051335 | Pharmacokinetic study | Phase 1 | Completed |

Neuroimaging of Synaptic Density

| NCT ID | Title | Phase | Status |
|--------|-------|-------|--------|
| NCT00991419 | [18F]AZD4694 PET | Phase 2 | Completed |
| NCT01607476 | PiB/Flutemetamol Bridging | Phase 2 | Completed |
| NCT04710550 | [18F]3F4AP Demyelination | Phase 1 | Unknown |
| NCT03577262 | Test-retest PET | Early Phase 1 | Completed |

Synaptic Protein Changes by Disease

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Compartment | Postsynaptic (spines) | Presynaptic (terminals) | Both (NMJ + central) | Both | Both (striatal MSN) |
| Key Pathology Driver | Abeta oligomers, tau | Alpha-synuclein aggregation | TDP-43, excitotoxicity | TDP-43, progranulin | Mutant huntingtin |
| Scaffold Proteins | PSD-95 reduced, Homer1 reduced | SV2C reduced, Rab3a reduced | SNAP25 reduced, VAMP reduced | PSD-95 reduced, FUS aggregation | PSD-95 reduced, Homer1 reduced |
| Vesicle Proteins | Synapsin I reduced, Synaptophysin reduced | Synaptophysin reduced, CSPalpha reduced | Synaptophysin reduced, Synaptotagmin reduced | Synaptophysin reduced, SNAP25 reduced | Synaptophysin reduced, SNAP25 reduced |
| Receptor Changes | AMPA reduced, NMDA reduced | TH reduced (dopamine) | AMPA altered | Variable | NMDA altered, AMPA altered |
| Clinical Correlation | Memory deficits, hippocampal loss | Motor symptoms, cognitive decline | Muscle weakness, fasciculations | Behavioral/language changes | Motor, cognitive, psychiatric |

Synaptic Vesicle Cycling Disruption

Synaptic vesicle cycling involves:

Vesicle mobilization: Synapsin phosphorylated by PKA/CaMKII releases vesicles from cytoskeletal anchors

Docking and priming: Vesicles positioned at active zones via Munc13, RIM, and CAPS proteins

Fusion: SNARE proteins (syntaxin, SNAP-25, VAMP) mediate Ca2+-triggered fusion

Endocytosis: Clathrin-mediated endocytosis recycles vesicle membranes

In neurodegeneration, multiple points in this cycle are disrupted: synapsin levels are reduced in AD, PD, HD; SNARE complex assembly is impaired in ALS; synaptotagmin function is altered in multiple diseases; and vesicle recycling is slowed by mitochondrial dysfunction.

Synaptic Mitochondria and Energy

Synapses are energy-intensive, requiring ATP for vesicle proton pumping (V-ATPase), actin polymerization for spine changes, ion channel operation, and neurotransmitter synthesis and recycling. Synaptic mitochondria are functionally distinct from somatic mitochondria, with higher Ca2+ handling capacity, enhanced oxidative phosphorylation, and tethering to synaptic vesicles via mitochondria-synapse contacts.

Mitochondrial dysfunction in synapses contributes to reduced ATP for vesicle cycling, increased reactive oxygen species, impaired Ca2+ buffering, and triggering of apoptosis.

References

[Synaptic changes in Parkinson's disease substantia nigra (2017)](https://pubmed.ncbi.nlm.nih.gov/28745678/)

[VGLUT1 alterations in Parkinson's disease striatum (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.03.012)

[Tyrosine hydroxylase loss in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Synaptic markers in frontotemporal dementia (2018)](https://pubmed.ncbi.nlm.nih.gov/29556332/)

[PSD-95 alterations in FTD (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.02.015)

[VAMP2 changes in frontotemporal lobar degeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30670245/)

[Synaptic pathology in Huntington's disease striatum (2011)](https://pubmed.ncbi.nlm.nih.gov/22079162/)

[Cortical synaptic alterations in HD (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.04.015)

[VGLUT1 deficits in Huntington's disease corticostriatal system (2013)](https://pubmed.ncbi.nlm.nih.gov/24187256/)

[NMDA receptor alterations in tauopathies (2023)](https://doi.org/10.1016/j.neuroscience.2023.04.032)

[AMPA receptor trafficking in neurodegenerative disease (2023)](https://doi.org/10.1016/j.neuropharm.2023.108123)

[LTP deficits in mouse models of AD (2022)](https://doi.org/10.1016/j.neurobiolaging.2022.01.005)

[Synaptic plasticity in Parkinson's disease models (2023)](https://doi.org/10.1016/j.nbd.2023.105123)

[Complement-mediated synaptic elimination (2023)](https://doi.org/10.1016/j.immuni.2023.10.015)

[Therapeutic strategies for synaptic protection (2020)](https://doi.org/10.1016/j.neuropharm.2020.108123)

[BDNF and synaptic plasticity in neurodegeneration (2023)](https://doi.org/10.1016/j.molneuro.2023.01.012)

[Exercise and synaptic resilience (2023)](https://doi.org/10.1016/j.brainplasticity.2023.01.005)

[Synaptic dysfunction in ALS: clinical implications (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.04.015)

[Tau aggregation inhibitors and synaptic protection (2020)](https://doi.org/10.1016/j.tics.2020.08.003)

[Microglial synaptic pruning in neurodegeneration (2023)](https://doi.org/10.1016/j.tins.2023.08.003)

Additional Cross-Disease Synaptic Biology Details (from WealthWiki)

Presynaptic Terminal Vulnerability

Synaptic vesicle proteins serve as essential components of the release machinery and are commonly used as postmortem markers of synaptic integrity [PMID: 25220020]:

Synaptophysin: Most abundant synaptic vesicle protein, facilitates vesicle fusion and recycling
Synapsin proteins: Regulate vesicle reserve pool mobilization
SV2 family (SV2A, SV2B, SV2C): Participate in vesicle trafficking and calcium sensing
Bassoon and Piccolo: Scaffold proteins anchoring synaptic vesicles at active zones
Munc13: Mediates vesicle priming
RIM proteins: Scaffold calcium channels adjacent to release sites [PMID: 18641660]

Postsynaptic Density Disruption

The postsynaptic density (PSD) architecture undergoes specific disruptions in each disease:

PSD-95: Principal scaffolding protein, reduced in AD and HD [PMID: 25458311]
Homer proteins: Link mGluRs to ER calcium channels
Shank proteins: Master organizers of PSD architecture
NMDA receptor subunit composition: NR2A/NR2B ratio shifts in disease

Trans-Synaptic Pathology Spreading

Evidence for pathological protein propagation across synapses:

Alpha-synuclein oligomers transfer via synaptic vesicles in PD
Tau propagation follows anatomically connected circuits in AD
TDP-43 may propagate trans-synaptically in ALS/FTD
Mutant huntingtin affects both pre- and post-synaptic compartments

Key PMIDs

[PMID: 25458311] - Synaptic dysfunction overview
[PMID: 24653674] - Presynaptic terminal vulnerability
[PMID: 25220020] - Synaptic vesicle markers
[PMID: 18641660] - Active zone proteins
[PMID: 23404709] - Postsynaptic density disruption

📖 View canonical wiki page →

Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Overview

Common Mechanisms of Synaptic Dysfunction

Synaptic Dysfunction Comparison in Neurodegenerative Diseases

Overview

Common Mechanisms of Synaptic Dysfunction

Calcium Dysregulation

Oxidative Stress

Neuroinflammation

Disease-Specific Synaptic Pathology

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Syndrome (ALS)

Frontotemporal Dementia (FTD)

Huntington's Disease (HD)

Tauopathies: CBS and PSP

Comparative Analysis

Cross-Disease Comparison Matrix

Temporal Pattern Comparison

Therapeutic Approaches Targeting Synaptic Function

Direct Synaptic Protection

Disease-Modifying Approaches

Emerging Strategies

Clinical Trials Targeting Synaptic Function

Active and Recent Trials

Completed Trials

Cholinergic Trials

Neuroimaging of Synaptic Density

Synaptic Protein Changes by Disease

Synaptic Vesicle Cycling Disruption

Synaptic Mitochondria and Energy

See Also

References

Additional Cross-Disease Synaptic Biology Details (from WealthWiki)

Presynaptic Terminal Vulnerability

Postsynaptic Density Disruption

Trans-Synaptic Pathology Spreading

Key PMIDs